The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, or HRS-1358 for advanced unresectable or metastatic breast cancer
Females aged 18-75 years (inclusive);
ECOG performance status (PS) score of 0-1;
Patients with histopathologically confirmed metastatic or unresectable locally advanced breast cancer;
Patients with advanced malignant solid tumors confirmed by histopathology or cytopathology, who have failed standard treatment, or for whom no effective standard treatment regimen is available, or who are unable to receive further standard treatment.
With symptomatic visceral metastases deemed unfit for endocrine therapy by the investigator;
With active brain metastases, carcinomatous meningitis, spinal cord compression, or a history of primary tumors of the central nervous system;
History of clinically significant cardiovascular disease, including;
Abnormal ECG findings, which are judged by the investigator to be clinically significant and and need to intervene;
9
Treatment groupsSee each treatment group below.